Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

• Published in: Digestive and liver disease Vol. 47; no. 2; pp. 157 - 163
• Main Authors: Cento, Valeria, Di Paolo, Daniele, Di Carlo, Domenico, Micheli, Valeria, Tontodonati, Monica, De Leonardis, Francesco, Aragri, Marianna, Antonucci, Francesco Paolo, Di Maio, Velia Chiara, Mancon, Alessandro, Lenci, Ilaria, Manunta, Alessandra, Taliani, Gloria, Di Biagio, Antonio, Nicolini, Laura Ambra, Nosotti, Lorenzo, Sarrecchia, Cesare, Siciliano, Massimo, Landonio, Simona, Pellicelli, Adriano, Gasbarrini, Adriano, Vecchiet, Jacopo, Magni, Carlo Federico, Babudieri, Sergio, Mura, Maria Stella, Andreoni, Massimo, Parruti, Giustino, Rizzardini, Giuliano, Angelico, Mario, Perno, Carlo Federico, Ceccherini-Silberstein, Francesca
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2015
• Subjects: Adult; Antiviral Agents - therapeutic use; Drug Therapy, Combination; Early response; Female; Gastroenterology and Hepatology; Hepacivirus - genetics; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Humans; Interferon-alpha - therapeutic use; Male; Middle Aged; NS3 protease inhibitors; Oligopeptides - therapeutic use; Polyethylene Glycols - therapeutic use; Prognosis; Proline - analogs & derivatives; Proline - therapeutic use; Ribavirin - therapeutic use; RNA, Viral - blood; Treatment Outcome; Viral kinetics; Viral Load; Virological failure; Virological failure; Early response; NS3 protease inhibitors; Viral kinetics

Abstract Background Triple therapy with telaprevir/boceprevir + pegylated-interferon + ribavirin can achieve excellent antiviral efficacy, but it can be burdened with resistance development at failure. Aims To evaluate kinetics of hepatitis C virus (HCV) RNA decay and early resistance development, i...